A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF BENDAMUSTINE AND RITUXIMAB (BR) ALONE VERSUS IN COMBINATION WITH ACALABRUTINIB (ACP-196) IN SUBJECTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA

Registry ID

ACE-LY-308

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ACERTA PHARMA BV

Start date

2020-12-01

Last update

2016-12-12

Conditions

• MANTLE CELL LYMPHOMA

Related clinical trials

• A PHASE II STUDY OF SONROTOCLAX PLUS ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PLANNED FOR STANDARD OF CARE CAR-T CELL THERAPY
• A MULTICENTRE, PHASE II, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY OF ACALABRUTINIB IN COMBINATION WITH VENETOCLAX AND RITUXIMAB IN PARTICIPANTS WITH TREATMENT NAÏVE MANTLE CELL LYMPHOMA (TRAVERSE).
• A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING GLOFITAMAB AS A SINGLE AGENT VERSUS INVESTIGATOR¿S CHOICE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
• A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY COMPARING ZANUBRUTINIB (BGB-3111) PLUS RITUXIMAB VERSUS BENDAMUSTINE PLUS RITUXIMAB IN PATIENTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA(MCL) WHO ARE INELIGIBLE FOR STEM CELL TRANSPLANTATION
• A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF LOXO-305 VERSUS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED BTK INHIBITOR NAÏVE MANTLE CELL LYMPHOMA (BRUIN MCL-321)
• A PHASE II STUDY OF ACALABRUTINIB IN COMBINATION WITH R-CHOP CHEMOTHERAPY IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA

View on source registry